Compare DexCom, Inc. (DXCM) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs FTAI Aviation Ltd — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while FTAI Aviation Ltd trades at $226.26 (market cap $23.17B). The key difference: DexCom, Inc. is the larger of the two by market cap, and FTAI Aviation Ltd pays a 0.89% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | FTAI | |
|---|---|---|
Market Cap | $33.79B | $23.17B |
Sector | Health | Industrials |
52-Week High | $89.53 | $310.04 |
52-Week Low | $54.84 | $140.40 |
Enterprise Value | $33.24B | $26.29B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
FTAI Aviation trades at $226.66, up 5.42% today, with a neutral technical signal and mixed earnings history. Recent quarters have seen EPS misses against expectations, though revenue grew to $2.51B in 2025. The company maintains strong profitability margins and a 100% buy rating from analysts, with a consensus price target of $341.67. Key developments include a strategic collaboration for Boeing 737-800 freighters and a $1.465B gas turbine order, highlighting growth initiatives in aviation services and power segments.
The outlook for FTAI is positive based on analyst consensus and strategic growth in aviation and power markets, but risks include earnings volatility, high valuation multiples, and execution challenges in new segments. The stock offers potential upside to price targets, supported by institutional interest and dividend increases, yet investors should weigh near-term earnings performance against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
